28.06.2012 - French theranostics and in vitro diagnostics company Theradiag is set to acquire its compatriot Prestizia, a specialist for microRNA-based diagnostics.
Paris/Marne la Vallee – Prestizia SAS is part of the Holding Incubatrice Biotechnology and Pharmacy, which was launched by Truffle Capital in 2010 and is presided by Jean-Jacques Bertrand, former CEO of Aventis-Pasteur. The company, which has been set up in April 2011 with a starting capital of €300,000, aims at developing novel diagnostic assays for viral infections and human malignancies based on microRNA expression and holds an exclusive license to a technology for characterising HIV cell tropism based on the identification of microRNA signatures.
“The acquisition of Prestizia represents a major advance for Theradiag. Its microRNA platform is going to allow us to strengthen our development in theranostics with a highly innovative, patented technology,” stated Michel Finance, CEO of Theradiag. The Marne la Vallee-based company changed its name from Biomedical Diagnostics (BMD) only last month, to reflect its drive to develop theranostic assays for monitoring the effects of biotherapeutics.
Theradiag pins primary hopes on the newly acquired microRNA technology, stating that it could have widespread clinical applications including identifying patients eligible for particular anti-HIV treatments or for differentiating different cancer types. The first application of this platform is already being developed, in collaboration with the Institut de Génétique Moléculaire de Montpellier (IGMM) for finalising a molecular biology test of HIV tropism to be marketed in the near future.
23.10.2014 Jean-Claude Juncker can breathe a sigh of relief as MEPs voted “yes” by a large majority to his team of European Union Commissioners. Previous to the vote, Juncker had shifted the EMA back to the health commissioner in response to protests.
21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.